February 2, 2023
ICER’s cost-effectiveness analysis doesn’t wholly depict
the value of new Alzheimer’s medications.
February 2, 2023
ICER released its draft evidence report on beta-amyloid antibodies for early Alzheimer’s disease.
January 4, 2023
Alzheimer’s disease and other forms of dementia have long impacted families
and communities across the country. Today, about 6 million Americans live
with Alzheimer’s disease — a number that will more than double by 2050.
February 22, 2022
ICER has announced its intent to issue a final evidence report in this review without first holding a public hearing, a highly unusual decision.
October 15, 2021
ICER’s priorities differ from severe asthma patients’, and the economists’ approach could make it harder for patients to access the…
October 12, 2021
Just as asthma impacts people differently, existing treatment options serve some patients better than others.
June 3, 2021
Alzheimer’s and dementia already afflict too many people, yet their prevalence is expected to more than double in the coming…
May 28, 2021
The Institute for Clinical and Economic Review claims that the first disease-modifying treatment for Alzheimer’s disease isn’t worth its cost.
April 30, 2021
An efficacious treatment that reduces the symptoms and risk factors associated with obstructive hypertrophic cardiomyopathy delivers great value to patients.…
December 10, 2020
The Institute for Clinical and Economic Review claims that new medications for high cholesterol aren’t worth their cost. The economists…
